Lumida
/AMLX
⌘K
Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc

AMLX
$31.62USD↓-1.46%-0.47 today

MARKET CAP

4.0B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$31 – $33

52W RANGE

$11
$41

AI Summary

Stalk
Sell NowMedium

AMLX has entered a Stage 3 distribution phase after a parabolic rally and now consolidates below its declining 9- and 20-day EMAs. Price has slipped below short-term moving averages with light volume, indicating rejection at resistance and lack of strong distribution support. Medium-term bias is bearish under the distribution regime, while the long-term uptrend remains intact above the 50- and 200-day SMAs but is currently overshadowed by near-term weakness.

  • ↑Phase III Lucidity trial showed significant reduction in hypoglycemic events, driving a 47% share rally.
  • ↑Avexitide targets ~160k U.S. post-bariatric hypoglycemia patients; endocrinologist surveys show strong treatment intent.
  • ↓FDA approval uncertainty looms over Avexitide’s planned 2027 launch.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Amylyx Pharmaceuticals (NASDAQ: AMLX) is a biopharmaceutical company focused on developing innovative therapies targeting underserved medical conditions within the endocrine space. The company is advancing its lead asset, Avexitide, a first-in-class GLP-1 receptor antagonist devised to address post-bariatric hypoglycemia (PBH). With a pivotal Phase III Lucidity trial underway and potential FDA approval expected in 2027, Amylyx stands at a significant junction to fulfill a crucial healthcare need, especially among post-bariatric surgery patients.

Bull says

  • ↑Phase III Lucidity trial showed significant reduction in hypoglycemic events, driving a 47% share rally.
  • ↑Avexitide targets ~160k U.S. post-bariatric hypoglycemia patients; endocrinologist surveys show strong treatment intent.
  • ↑Q2 cash and marketable securities of $250.8M fund operations through 2028.
  • ↑High institutional ownership underscores strong investor backing ahead of FDA decision.
  • ↑Disease‐state education campaign boosts provider awareness, supporting future adoption.
  • ↑Positive momentum factors suggest further upside if NDA meets FDA expectations.

Bear says

  • ↓FDA approval uncertainty looms over Avexitide’s planned 2027 launch.
  • ↓Q2 operating expenses rose 7% YoY to $45.7M, heightening cash burn risk.
  • ↓High leverage risk and weak profitability factors pose financing challenges.
  • ↓Declining analyst sentiment and low earnings yield may deter investors.
  • ↓Physician adoption may lag due to ongoing educational gaps on PBH.

Investment themes with AMLX

Pharmaceuticals↓ -0.48%

Drug development driving global healthcare solutions

JNJ · LLY · RPRX

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 05-13-2025neutral

Transcript signals

Bull points

  • For Wolfram, we are seeing early evidence of benefit across multiple organ systems based on well-established outcomes such as c-peptide response. These results are consistent with our prior preclinical studies.
  • We plan to meet with FDA to discuss next steps in the program.
  • AMX0114 is a potent antisense oligonucleotide targeting inhibition of Calpain-2, a well-established target in a number of neurological diseases and published data suggest Calpain-2 is the primary protease that plays neurofilament light chain. We expect to enroll the first participants in our ALS trial later this year.

Bear points

  • The top-line results from the PHOENIX trial of AMX0035 and ALS were deeply disappointing and surprising given the prior CENTAUR trial results that had showed a meaningful benefit of AMX0035 for people living with ALS and supported an FDA approval.
  • Net product revenues were $88.6 million for the first quarter, down from $108.4 million in the fourth quarter of 2023.
  • For modeling purposes, you should anticipate us reporting no meaningful revenues after March 8th.
Read full transcript analysis ›